ABSTRACT
INTRODUCTION
Psoriasis is a common chronic immune-mediated inflammatory skin disease affecting 0.5-3% of the world's population, born of the complex interaction of the innate and adaptive immune systems together with a wide array of genetic pathways [1] [2] [3] [4] . It is associated with decreased quality of life and multiple comorbid conditions, including the metabolic syndrome and cardiovascular disease [5, 6] . Plaque psoriasis, the most common variant of psoriasis, is characterized by well-demarcated, erythematous plaques with Electronic supplementary material The online version of this article (doi:10.1007/s13555-015-0092-3) contains supplementary material, which is available to authorized users. adherent silvery scales [1] . Approximately 1.2 million patients (17%) in the US with plaque psoriasis have moderate-to-severe disease, often defined as psoriasis covering at least 10% of the body surface area or causing significant quality of life impairment [4] .
Although the pathogenesis of psoriasis is not completely understood, multiple environmental factors, T cells, dendritic cells, numerous cytokines, and 45 identified gene loci all interact to create the systemic psoriatic disease state and ultimately psoriatic plaques [1, 7] . Affected keratinocytes activate dendritic cells, which then travel to local lymph nodes and release several cytokines including interleukin (IL)-12 and IL-23, which activate type 1 T helper (T h 1) and type 17 T helper (T h 17) cells, respectively [8] . T lymphocytes and other cell types release additional cytokines, including tumor necrosis factor (TNF)-a, IL-22, and IL-17, leading to increased keratinocyte activation and the initiation of a self-propelled cycle of inflammation [1, 9] . Although earlier models focused on T h 1 cells as the central cell type for psoriasis pathogenesis, newer models focus on the IL-23/T h 17 axis [9] . In this model, IL-17 is secreted by T h 17 cells and is seen as one of the most important cytokines in psoriasis, while IL-23 drives T h 17 cell activation [9] .
Recent research indicates that both IL-23 and IL-17 play important, and perhaps integral, roles in the development of psoriatic plaques [8, 10, 11] . IL-23 is a pro-inflammatory cytokine produced predominately by inflammatory myeloid cells [12] . IL-23 is heterodimer comprised of a p40 subunit, which it has in common with IL-12, and a p19 subunit unique to IL-23. IL-23 signals via the IL-23R and IL-23Rb1 receptors [12] . As such, the success of IL-12/23p40 antagonists in treating plaque psoriasis is likely the result of a decrease in IL-23 rather than IL-12, as evidenced by increased IL-12/23p40 and IL23p19 in psoriatic plaques but no corresponding increase in IL-12p35 [9] . IL-23, in the presence of IL-6 and transforming growth factor (TGF)-b, stimulates the differentiation of T cells to T h 17 cells and plays an integral role in the survival of these cells [12] [13] [14] . This stimulation of T h 17 cells leads to an increase in the release of IL-17 [8] .
IL [49] . In the same study, 69.0% of subjects on 300 mg, 52.5% of subjects on 150 mg, and 0% of subjects on placebo achieved a score of 0 or 1 on the 2011 modified Investigator's Global Assessment [49] . This study also reported high usability of a prefilled syringe with a safety profile similar to previous studies [49] .
A study comparing retreatment-as-needed secukinumab versus fixed-interval secukinumab was unable to show a statistically significant difference between the two dosing methods, although the rates of those achieving and maintaining PASI 75 were numerically higher in the fixed-interval group [50] Additionally, 30.8-40.5% of the patients achieved PASI 100 (complete clearance) at 12 weeks [52] . High levels of response were maintained through 60 weeks of treatment [52] .
The most common adverse events seen in these trials were nasopharyngitis and injection site reactions, with rates and severity comparable to etanercept [52] . Additional studies are ongoing.
DRUGS TARGETING IL17RA
Brodalumab Brodalumab (AstraZeneca) is unique among the biologic drugs targeting IL-17, as it is a fully human monoclonal antibody targeting the IL-17 receptor A (IL-17RA) rather than the IL-17A cytokine itself [53] . It inhibits binding of several members of the IL-17 cytokine family, including IL-17A and IL-17F, to the receptor [53] . In May 
